Skip to content
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us

rare genetic disorder

  1. Home>
  2. News and Events>
  3. rare genetic disorder
Read more about the article EMA recommends authorisation of first therapy to treat rare genetic disorder

EMA recommends authorisation of first therapy to treat rare genetic disorder

  • Post published:June 16, 2022

EMA has recommended granting a marketing authorisation in the European Union for Upstaza (eladocagene exuparvovec). This is a gene therapy for the treatment of adult and paediatric patients with severe…

Continue ReadingEMA recommends authorisation of first therapy to treat rare genetic disorder

Revio is a Regulatory Affairs Consultancy – Created to support biopharmaceutical companies and public institutions, working with Advanced Therapy Medicinal Products (ATMPs)

Facebook-f Twitter Pinterest Linkedin

About

Home

About Us

Services

News & Events

Contact Us

Contact

TELEPHONES

+34 656 659 636

EMAIL

regaffairs@reviopharma.com

Legal

Cookies Policy

Data Protection

Legal Notice

Privacy policy

Social Networks

Copyright © 2024 – All Right Reserved – Powered by: Headteam.marketing

Reviopharma
×

Cart